![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » China Approves Early Stage Trial of Pfizer and BioNTech’s COVID-19 Vaccine
China Approves Early Stage Trial of Pfizer and BioNTech’s COVID-19 Vaccine
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/China_Map.gif?t=1478215210&width=430)
China’s National Medical Products Administration has approved a phase 1 trial of Pfizer and BioNTech’s mRNA-based COVID-19 vaccine candidate BNT162b1.
The trial will be conducted by Fosun Pharma, which entered into a collaboration agreement with BioNTech in March to develop and commercialize the vaccine in China. Fosun said it will initiate the trial “as soon as possible.”
The FDA granted BNT162b1 a fast track review designation earlier this week along with their other mRNA vaccine candidate BNT162b2.
Upcoming Events
-
21Oct